Articles

Three investigational diet drugs hold promise for preventing and treating diabetes. The findings show that the drugs can help “halt the progression towards Type 2 diabetes.

Novo Nordisk experimental diabetes drug liraglutide was significantly better at helping patients control blood sugar than an older common medicine after two years of treatment, according to data from a clinical trial.

Retrospective Cohort Study included more than 25,000 BYETTA patients accrued over three years … Full Story

The findings of two 52-week studies show that the investigational ultra rapid acting insulin AFRESA® (insulin human [rDNA origin]) Inhalation Powder combined with basal insulin is comparable to standard of care therapies in controlling post-meal blood sugar levels, and also results in significantly less weight gain and risk of hypoglycemia …

Once-weekly exenatide (EQW) produces superior improvements in glucose control and body weight compared with maximum daily doses of sitagliptin and pioglitazone on background metformin, according to study results presented at the American Diabetes Association (ADA) 69th Scientific Sessions.

Researchers at the ADA reported that Liraglutide reverses prediabetes indices in most obese patients with existing prediabetes …Full Story

Lower hemoglobin A1c levels alone don’t appear to increase mortality risk with intensive glucose control, subanalyses of two major diabetes trials revealed. Each 1% lower average HbA1c was associated with a 56% lower relative risk of mortality. Diabetes patients had reduced composite cardiovascular event and mortality rates with intensive glucose …

If you are pregnant and your mate complains your frequent snoring is rattling the bedroom windows, you may have bigger problems than an annoyed, sleep-deprived partner

Diabetic patients with poor glycemic control or vascular or neuropathic complications may also suffer from hearing loss. All patients with hemoglobin A1c levels greater than 7% had hearing impairment.

Saxagliptin, an investigational dipeptidyl peptidase-4 (DPP4) inhibitor, may offer cardioprevention as a side benefit of diabetes treatment, according to a meta-analysis.